CeriBell (NASDAQ:CBLL – Get Free Report) is expected to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect CeriBell to post earnings of ($0.32) per share and revenue of $17.55 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
CeriBell Stock Performance
CeriBell stock opened at $24.69 on Friday. The business’s fifty day moving average is $23.53. CeriBell has a one year low of $18.69 and a one year high of $32.75.
Analyst Ratings Changes
A number of research analysts recently commented on CBLL shares. Bank of America began coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price for the company. Canaccord Genuity Group upped their price target on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 9th. TD Cowen lifted their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Canaccord Genuity Group started coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.60.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
- Five stocks we like better than CeriBell
- Short Selling: How to Short a Stock
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What Are the FAANG Stocks and Are They Good Investments?
- DuPont’s Electronics Spinoff: The Start of Something Big
- Stock Dividend Cuts Happen Are You Ready?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
